Aarti Drugs nears 5-year high; stock rallies 26% in 5 days in a weak market
Analysts believe the firm's API business will continue its growth momentum driven by capacity expansion and gain in market share in existing products27-02-2020
27-02-2020
Aarti Drugs Ltd - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificates / Issue of Duplicate Share Certificates under Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.17-02-2020
Aarti Drugs Ltd - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificates / Issue of Duplicate Share Certificates under Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 201511-02-2020
Aarti Drugs Ltd - 524348 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release for December'1907-02-2020
Aarti Drugs Ltd - 524348 - Fixes Record Date for Interim Dividend
Aarti Drugs Ltd has informed BSE that the Company has fixed February 18, 2020 as the Record Date for the purpose of Payment of Interim Dividend.07-02-2020
Aarti Drugs Ltd - 524348 - Corporate Action-Board approves Dividend
We wish to inform you that Board of Directors of the Company at its Meeting held on Thursday, February 6, 2020, has declared the Interim Dividend @ Rs.2/- ( 20%) per Equity share for the financial year 2019-20. Please note that as per Regulation 42(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Tuesday, February 18, 2020 has been fixed as 'Record Date' for the purpose of payment of Interim Dividend.06-02-2020
Aarti Drugs Ltd - 524348 - Audited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended December 31, 2019
We wish to inform you that the Board of Directors at its Meeting held on Thursday, February 6, 2020, approved the Audited Standalone and Consolidated Financial Results for the Quarter and nine months ended December 31, 2019. Pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015 we enclose the following:- Audited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2019. Auditor's Report on Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2019.06-02-2020
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This is to inform you that Quarterly Conference Call for the Investors and Analysts has been scheduled on Friday, February 7, 2020 at 3:00 PM IST to discuss the Company's Q3 FY20 Results.05-02-2020
AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificates04-02-2020
Aarti Drugs Ltd - 524348 - Board to consider Interim Dividend
Aarti Drugs Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled to be held on February 06, 2020, inter-alia to;1. Consider, approve and take on record Audited Financial Results (Standalone and Consolidated) for the Quarter and Nine months ended December 31, 2019.2. Consider and declare Interim Dividend for the FY 2019-20, if any.30-01-2020